Public Release: 

Insilico to present the advances in Artificial Intelligence for Healthcare in Kenya

InSilico Medicine, Inc.


IMAGE: Iraneus Ogu, Africa AI, Blockchain and Longevity Consultant in Insilico Medicine, will present at the Kenya Medical Association 46th Annual Scientific Conference in Mombasa, Kenya, April 21, 2018. view more 

Credit: Insilico Medicine

Tuesday, April 17th, 2018, Baltimore, MD - Insilico Medicine, a Baltimore-based company specializing in the application of artificial intelligence for drug discovery, biomarker development and aging research, announces the presentation of its Africa AI, Blockchain and Longevity Consultant, Iraneus Ogu, at the KMA 46th Annual Scientific Conference, April 21, 2018, Mombasa, Kenya.

Ogu's presentation "Building the African pharmaceutical industry and the future of longevity with next-generation artificial intelligence" will focus on the latest advances in artificial intelligence tending to become a growth engine for African biopharmaceutical industry and transform the R&D in local pharmaceutical companies. The talk will also be devoted to the challenges of African pharmaceutical sector and to the educational opportunities for building the strong local teams interested in the application of AI to drug discovery processes.

"We are very happy to present our work at the Kenya Medical Association Annual Scientific Conference, which brings together many African experts from pharmaceutical and healthcare industry as well as from education. The topic of Artificial Intelligence for pharma R&D is rapidly gaining popularity and we are happy to be at the leading edge of research and one of the innovation drivers in this area", said Alex Zhavoronkov, PhD, the founder and CEO of Insilico Medicine, Inc.

"The digital revolution in healthcare led to the immense amount of data that are generated daily, and these data could be channeled towards the better products in healthcare. However, many people in the world, especially in Africa, do not yet realize the value of their personal data including the medical records. At the same time, there is a clear need to develop better solutions to many global healthcare challenges in addition to more local challenges in places like Africa. Herein we could converge advances in next-generation artificial intelligence and blockchain to accelerate developments in many aspects of healthcare and beyond", said Iraneus Ogu, Africa AI, Blockchain and Longevity Consultant of Insilico Medicine, Inc.

The Kenya Medical Association Annual Scientific Conference is organized by Kenya Medical Association (KMA) supporting the healthcare specialists and promoting the practice of medicine in Kenya. The event sets up its mission as the contributing to the professional development of doctors as well as the improvement of healthcare in Kenya and Eastern Africa in general. In 2018 KMA is celebrating its 50th anniversary and gathering the healthcare thought leaders around the "Healthcare Financing Towards Universal Health Coverage" theme. The conference will be held on April 18-21, 2018.


Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first who applied deep generative adversarial networks (GANs) to the generation of new molecular structures with specified parameters and published seminal papers in Oncotarget and Molecular Pharmaceutics. The paper published in Molecular Pharmaceutics in 2016 demonstrated the proof of concept of the application of deep neural networks for predicting the therapeutic class of the molecule using the transcriptional response data, received the American Chemical Society Editors' Choice Award. A recent paper published in November 2017 described the application of the next-generation AI and blockchain technologies to return the control over personal data back to the individual. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The most recent paper published in Oncotarget presented the roadmap to enhancing radioresistance for space exploration and colonization.

For further information, images or interviews, please contact:

Contact: Qingsong Zhu, PhD


Official Conference Websites:

About Insilico Medicine, Inc

Insilico Medicine, Inc. is an artificial intelligence company headquartered at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore, with R&D and management resources in Belgium, Russia, UK, Taiwan and Korea sourced through hackathons and competitions.

The company utilizes advances in genomics, big data analysis, and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI and Aging.AI and operates Chemistry.AI intended to capture the tacit knowledge of medicinal chemists.

Through a partnership with the BitFury Group, the company is working on a range of AI solutions for blockchain to help return the power over life data back to the individual. The company raised venture capital and partnered with Juvenescence Limited, a holding company focused on longevity biotechnology. The company aspires to become the "Bell Labs" for artificial intelligence and associated technologies for healthcare and longevity biotechnology and commercialize its research by forming subsidiaries around the specific technologies and licensing the intellectual property, molecules and data to the biotechnology and pharmaceutical companies. In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. Brief company video:

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.